Page 2 - க்ரெசந் ஶ்வைட்ஸர் வலேரியா மீனவர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reschedules the Reporting of the Full Year 2020 Financial Results to April 30, 2021 Email: vivoryon@trophic.eu About Vivoryon Therapeutics N.V. With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon s scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), in Alzheimer s disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury. www.vivoryon.com

Noord hollandUlrich dauerHalle saaleGretchen schweitzer valeria fisherCompany board of directorsNews serviceTrophic communicationsDistribution servicesFull yearEuronext amsterdamCorporate newsRegulatory announcementsUnofficial marketநூற்த் ஹாலண்ட்உல்ரிச் அச்சுறுத்தல்ஹால் ஸேயேல்